Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 10Thoracic 5Genitourinary 4Gastrointestinal 3Sarcoma 2Other solid neoplasm 2Head & Neck 2Gynecologic 2Lymphoid 1Breast 1

Conditions

Recurrence 5Lymphoma, Extranodal NK-T-Cell 5Lymphoma 5Hodgkin Disease 5Lymphoma, Large B-Cell, Diffuse 3Lymphoma, Follicular 3Lymphoma, T-Cell, Peripheral 2Solid Tumor 1Neoplasms 1Melanoma 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, T-Cell 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, B-Cell, Marginal Zone 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia 1Immunoblastic Lymphadenopathy 1Carcinoma, Non-Small-Cell Lung 1B-cell Malignancies 1

Interventions

pembrolizumab 14Nivolumab 9Specimen Handling 4Magnetic Resonance Spectroscopy 4fludarabine 3atezolizumab 3Ipilimumab 3Drug Therapy 3Cyclophosphamide 3epacadostat 2entrectinib 2durvalumab 2X-Rays 2Sirolimus 2Radiotherapy 2Radiation 2Methods 2Interleukin-2 2Injections 2CTLA-4 Antigen 2Blood Specimen Collection 2Biopsy 2zimberelimab 1vocimagene amiretrorepvec 1varlilumab 1utomilumab 1ulixertinib 1tremelimumab 1trastuzumab biosimilar HLX02 1trametinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Melanoma × tislelizumab × Lymphoid × Clear all
NCT04261439 2025-05-06

A Phase I/Ib Study of NIZ985 Alone and in Combination With Spartalizumab

Novartis

Phase 1 Terminated
60 enrolled
DermatologicLymphoidThoracic

Carcinoma, Non-Small-Cell Lung, Lymphoma, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡